Spotting Ebola in the Crowd New field test can rapidly discern between the real thing and lookalike fevers

Ebola virus, pictured here, can cause fevers that are hard to distinguish from malaria and other infections at their outset. A new diagnostic system could make it easier for clinicians working in remote locations to quickly weed out who really has Ebola and who doesn’t. Image courtesy of NIAID

At a clinic in Liberia, people trickle in from the surrounding neighborhoods, shivering despite the warm air, reporting varying degrees of headaches and nausea. Many of them are anxious—it’s 2014 and an Ebola outbreak is underway and they fear the worst: that they, like some of their neighbors and loved ones, have contracted the highly fatal disease. One by one, they wait to be examined by a clinician, all the while mosquitoes float and buzz in the thick evening air.

During the early stages of Ebola, symptoms are often hard to distinguish from another disease endemic to the region, malaria, a mosquito-borne blood infection caused by a parasite. Without an instantaneous way of screening a patient’s blood, people sick with malaria, instead of being treated with antimalarial medication, could be placed into quarantine and surrounded by other ill people who ultimately might, in fact, have Ebola and be highly contagious.

That danger of being unable to diagnose Ebola—or malaria—in seconds or minutes, rather than hours or days, is one of the major deficiencies that contributed to the 2014–2016 West Africa Ebola crisis, according to the Paul G. Allen Family Foundation.

“The standard diagnostic tests that exist are very good, but they’re hard to do out in the field in the middle of an outbreak like we saw in West Africa,” says John Connor, a Boston University School of Medicine associate professor of microbiology. Instead, samples need to be sent to a facility capable of running the tests. “It could be several days between taking a sample and getting a diagnosis.”

When dealing with a fast-spreading, highly contagious, deadly disease like Ebola, those several days could mean the difference between containing an outbreak—or not.

Learning from the Past

Connor, in collaboration with researchers from Columbia University, the National Institutes of Health Integrated Research Facility, and clinical partners from Senegal and the Hemorrhagic Fever Lab at Université Gamal Abdel Nasser de Conakry, Guinea, as well as BD (Becton Dickinson), a global medical technology company, teamed up to do something about it. The international team, led by BD, proposed an idea for a new kind of diagnostic that would bridge critical gaps in the field. The Allen Foundation agreed to fund the idea.

“We set out to create a rapid, point-of-care diagnostic that could look for malaria, Ebola, and other pathogens that are often found in these regions,” says Connor, a virologist at the BU National Emerging Infectious Diseases Laboratories (NEIDL), which contains a Biosafety Level-4 laboratory that has been working with Ebola virus since August 2018.

As he reflects on the West Africa outbreak that prompted the last two years of his research efforts, Connor says better diagnostics are needed just as much now as ever. In the Democratic Republic of the Congo, Connor says, is “a smoldering outbreak…the largest outbreak that Congo has ever had and it’s looking like it’s not under control.”

Ray of Light for Remote Clinics

While there are myriad ways to design rapid, portable diagnostics, the solution pursued by the team was based on a test that could be stored without refrigeration, which is typically hard to maintain along supply routes to rural outbreak areas. That’s why a compact diagnostic system built on magnetic beads and glass-encased gold nanoparticles was so appealing for the job.

The system, surface-enhanced Raman scattering (SERS), is based upon the idea that light scatters off of different types of molecules in distinct ways. Specific molecules have distinct light-scattering signatures, or unique barcodes, that can be detected. Although the barcodes can be weak on their own, adding gold particles makes the barcode easier to detect by boosting the light signal.

“Gold amplifies the barcode by about a million times,” says Connor.

Partnering with BD, which had developed SERS for other global-health-related applications, Connor and his collaborators helped design a system that would be able to differentiate between various barcodes of the malarial parasite and Ebola virus, as well as Marburg and Lassa viruses, two other deadly hemorrhagic fevers found in the same regions of Africa where Ebola outbreaks occur.

At the start of the test, a small sample of blood is mixed with magnetic beads coated in antibodies that attract each of the four infectious agents. If the blood contains malaria-causing parasites or Ebola, Marburg, or Lassa viruses, the pathogens glom onto the magnetic beads. At the same time, similar antibodies on glass-encased gold nanoparticles also attach to the pathogens, creating a link between the magnetic and gold beads. Then, inside a small machine, the materials are concentrated into one spot by magnetic force and hit with a small laser beam.

Diagnosis in a Flash

Analyzing the barcode of light that flashes back from a sample, the machine provides a readout of the presence of malarial parasites or Ebola, Marburg, or Lassa viruses. If a sample contains more than one infectious agent, the test is able to identify them all.

From sample-taking to final readout, the entire process can be completed in a half hour or less. The development of the system, and experimental data showing its efficacy in animal and human blood samples, was published December 12, 2018, in Science Translational Medicine.

According to one of the study’s coauthors, Yanis Ben Amor of Columbia University, who partnered with lab technicians in Africa to test the device in the actual field, a great benefit is that “once the sample is added to the tube, there is no need to reopen the tube since all the reagents are already inside.” For the technicians carrying out the testing, “this was seen as a tremendous advantage in the context of highly infectious samples.” Souleymane Mboup, an epidemiologist in Senegal and another co-author on the study, agrees. A key advantage of this platform, Mboup says, is its ability to detect multiple deadly infections all from a single patient sample contained within one test tube.

Designed to go anywhere, the system’s components can be battery operated and can fit inside a backpack. How does Connor know that? He’s stuffed them inside his own standard-sized backpack to test out its portability.

“The implications for getting good diagnostics to remote places are huge,” says Connor, who is a corresponding author of the study.

Connor says that the value of the diagnostic goes beyond identifying who has a contagious illness and who does not. It’s also about building stronger relations with the communities at risk of becoming infected.

During an outbreak, “there is a strain between clinicians who are trying to assist with limited resources and the local community that is losing trust in their healthcare workers because they don’t have the appropriate tools and therefore can’t help to their fullest capability,” says Ben Amor.

If patients can rapidly be diagnosed and treated for illness, it can foster trust while immediately helping clinicians identify who should be quarantined and who should be sent home with antimalarial medicines.

The best scenario would be that clinicians are able to limit the time patients wait in crowded rooms, and therefore, decrease transmission opportunities, says Ben Amor.

Connor adds that the system could be custom-tailored to detect and differentiate virtually any combination of pathogens—bacterial, viral, fungal, or parasitic.

“The reason I find this system so promising is that it can diagnose more than one thing, which is important in the real-world context of infectious diseases,” Connor says. “The disease landscape is complicated and pathogens aren’t operating in isolation from one another.”